Berger Labor

Ausgewählte Publikationen

Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness
Gabler L, Jaunecker CN, Katz S, van Schoonhoven S, Englinger B, Pirker C, Mohr T, Vician P, Stojanovic M, Woitzuck V, Laemmerer A, Kirchhofer D, Mayr L, LaFranca M, Erhart F, Grissenberger S, Wenninger-Weinzierl A, Sturtzel C, Kiesel B, Lang A, Marian B, Grasl-Kraupp B, Distel M, Schüler J, Gojo J, Grusch M, Spiegl-Kreinecker S, Donoghue DJ, Lötsch D, Berger W.
Acta Neuropathol Commun. 2022 Apr 28;10(1):65. doi: 10.1186/s40478-022-01363-2.

Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound
Ertl IE, Lemberger U, Ilijazi D, Hassler MR, Bruchbacher A, Brettner R, Kronabitter H, Gutmann M, Vician P, Zeitler G, Koren A, Lardeau CH, Mohr T, Haitel A, Compérat E, Oszwald A, Wasinger G, Clozel T, Elemento O, Kubicek S, Berger W, Shariat SF.
Eur Urol. 2022 Apr 4:S0302-2838(22)01678-5. doi: 10.1016/j.eururo.2022.03.009.

The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation
Baier D, Schoenhacker-Alte B, Rusz M, Pirker C, Mohr T, Mendrina T, Kirchhofer D, Meier-Menches SM, Hohenwallner K, Schaier M, Rampler E, Koellensperger G, Heffeter P, Keppler B, Berger W.
Pharmaceutics. 2022 Jan 20;14(2):238. doi: 10.3390/pharmaceutics14020238.

Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup.
Pirker C, Bilecz A, Grusch M, Mohr T, Heidenreich B, Laszlo V, Stockhammer P, Lötsch-Gojo D, Gojo J, Gabler L, Spiegl-Kreinecker S, Doeme B, Steindl A, Klikovits T, Hoda MA, Jakopovic M, Samarzija M, Mohorcic K, Kern I, Kiesel B, Brcic L, Oberndorfer F, Müllauer L, Klepetko W, Schmidt WM, Kumar R, Hegedus B, Berger W.
Clin Cancer Res. 2020 Jul 15;26(14):3819-3830. doi: 10.1158/1078-0432.CCR-19-3573.

Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib.
Englinger B, Laemmerer A, Moser P, Kallus S, Röhrl C, Pirker C, Baier D, Mohr T, Niederstaetter L, Meier-Menches SM, Gerner C, Gabler L, Gojo J, Timelthaler G, Senkiv J, Jäger W, Kowol CR, Heffeter P, Berger W.
Int J Cancer. 2020 Sep 15;147(6):1680-1693. doi: 10.1002/ijc.32924.

Single-cell RNA-seq reveals cellular hierarchies and impaired developmental trajectories in pediatric ependymoma.
Gojo J, Englinger B, Jiang L, et al., Berger W, Kool M, Filbin MG.
Cancer Cell. 2020 Jul 13;38(1):44-59.e9. doi: 10.1016/j.ccell.2020.06.004.

Metal drugs and the anticancer immune response.
Englinger B, Pirker C, Heffeter P, Terenzi A, Kowol CR, Keppler BK, Berger W.
Chem Rev. 2019 Jan 23;119(2):1519-1624. doi: 10.1021/acs.chemrev.8b00396.

Alle Publikationen

PubmedDatabase